Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer

K. Mimori, Y. Tanaka, K. Yoshinaga, T. Masuda, K. Yamashita, M. Okamoto, H. Inoue, M. Mori

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Background: By using array comparative genomic hybridization (CGH), the increased copy number of CYP24 (which encodes vitamin D 24-hydroxylase) at 20q13.2 was previously reported, leading to the identification of CYP24 as a candidate oncogene in breast cancer. CYP24 leads to abrogate growth control mediated by vitamin D. Materials and methods: We examined CYP24 expression as well as VDR (vitamin D receptor) gene expression in 42 esophageal cancer cases using semi-quantitative RT-PCR assay. We induced CYP24 in seven esophageal cancer cell lines using 25-hydroxyvitamin D3 [25(OH D3] and compared cell growth rate, measured using the 3-(4, 5-dimethylthiazol-2-y)-2, 5-diphenyltetrazolium bromide (MTT) assay system. Results: The overall survival rate was significantly higher in 25 cases of lower CYP24 expression than 17 cases of higher CYP24 expression (P <0.05); on the other hand, 23 cases of low VDR expression had a poorer prognosis than 19 cases of high VDR expression. Moreover, we disclosed that the inverse correlation between CYP24 and VDR expression is significant in esophageal cancer cases (P <0.05). Furthermore, the cell growth evaluated by MTT assay was greatly increased in CYP24-induced and VDR-diminished cells than non-responding cells by 25(OH)D3 activity (P <0.01). Conclusions: Overexpression of the candidate oncogene CYP24 is inversely correlated to vitamin D receptor expression, and may play an important role in determination of the malignant potential of esophageal cancer.

Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalAnnals of Oncology
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 1 2004

Fingerprint

Calcitriol Receptors
Esophageal Neoplasms
Oncogenes
Growth
Calcifediol
Comparative Genomic Hybridization
Bromides
Vitamin D
Breast Neoplasms
Gene Expression
Cell Line
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. / Mimori, K.; Tanaka, Y.; Yoshinaga, K.; Masuda, T.; Yamashita, K.; Okamoto, M.; Inoue, H.; Mori, M.

In: Annals of Oncology, Vol. 15, No. 2, 01.02.2004, p. 236-241.

Research output: Contribution to journalArticle

Mimori, K. ; Tanaka, Y. ; Yoshinaga, K. ; Masuda, T. ; Yamashita, K. ; Okamoto, M. ; Inoue, H. ; Mori, M. / Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. In: Annals of Oncology. 2004 ; Vol. 15, No. 2. pp. 236-241.
@article{8c081c61e12b41a8b59bce68c87387f6,
title = "Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer",
abstract = "Background: By using array comparative genomic hybridization (CGH), the increased copy number of CYP24 (which encodes vitamin D 24-hydroxylase) at 20q13.2 was previously reported, leading to the identification of CYP24 as a candidate oncogene in breast cancer. CYP24 leads to abrogate growth control mediated by vitamin D. Materials and methods: We examined CYP24 expression as well as VDR (vitamin D receptor) gene expression in 42 esophageal cancer cases using semi-quantitative RT-PCR assay. We induced CYP24 in seven esophageal cancer cell lines using 25-hydroxyvitamin D3 [25(OH D3] and compared cell growth rate, measured using the 3-(4, 5-dimethylthiazol-2-y)-2, 5-diphenyltetrazolium bromide (MTT) assay system. Results: The overall survival rate was significantly higher in 25 cases of lower CYP24 expression than 17 cases of higher CYP24 expression (P <0.05); on the other hand, 23 cases of low VDR expression had a poorer prognosis than 19 cases of high VDR expression. Moreover, we disclosed that the inverse correlation between CYP24 and VDR expression is significant in esophageal cancer cases (P <0.05). Furthermore, the cell growth evaluated by MTT assay was greatly increased in CYP24-induced and VDR-diminished cells than non-responding cells by 25(OH)D3 activity (P <0.01). Conclusions: Overexpression of the candidate oncogene CYP24 is inversely correlated to vitamin D receptor expression, and may play an important role in determination of the malignant potential of esophageal cancer.",
author = "K. Mimori and Y. Tanaka and K. Yoshinaga and T. Masuda and K. Yamashita and M. Okamoto and H. Inoue and M. Mori",
year = "2004",
month = "2",
day = "1",
doi = "10.1093/annonc/mdh056",
language = "English",
volume = "15",
pages = "236--241",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer

AU - Mimori, K.

AU - Tanaka, Y.

AU - Yoshinaga, K.

AU - Masuda, T.

AU - Yamashita, K.

AU - Okamoto, M.

AU - Inoue, H.

AU - Mori, M.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Background: By using array comparative genomic hybridization (CGH), the increased copy number of CYP24 (which encodes vitamin D 24-hydroxylase) at 20q13.2 was previously reported, leading to the identification of CYP24 as a candidate oncogene in breast cancer. CYP24 leads to abrogate growth control mediated by vitamin D. Materials and methods: We examined CYP24 expression as well as VDR (vitamin D receptor) gene expression in 42 esophageal cancer cases using semi-quantitative RT-PCR assay. We induced CYP24 in seven esophageal cancer cell lines using 25-hydroxyvitamin D3 [25(OH D3] and compared cell growth rate, measured using the 3-(4, 5-dimethylthiazol-2-y)-2, 5-diphenyltetrazolium bromide (MTT) assay system. Results: The overall survival rate was significantly higher in 25 cases of lower CYP24 expression than 17 cases of higher CYP24 expression (P <0.05); on the other hand, 23 cases of low VDR expression had a poorer prognosis than 19 cases of high VDR expression. Moreover, we disclosed that the inverse correlation between CYP24 and VDR expression is significant in esophageal cancer cases (P <0.05). Furthermore, the cell growth evaluated by MTT assay was greatly increased in CYP24-induced and VDR-diminished cells than non-responding cells by 25(OH)D3 activity (P <0.01). Conclusions: Overexpression of the candidate oncogene CYP24 is inversely correlated to vitamin D receptor expression, and may play an important role in determination of the malignant potential of esophageal cancer.

AB - Background: By using array comparative genomic hybridization (CGH), the increased copy number of CYP24 (which encodes vitamin D 24-hydroxylase) at 20q13.2 was previously reported, leading to the identification of CYP24 as a candidate oncogene in breast cancer. CYP24 leads to abrogate growth control mediated by vitamin D. Materials and methods: We examined CYP24 expression as well as VDR (vitamin D receptor) gene expression in 42 esophageal cancer cases using semi-quantitative RT-PCR assay. We induced CYP24 in seven esophageal cancer cell lines using 25-hydroxyvitamin D3 [25(OH D3] and compared cell growth rate, measured using the 3-(4, 5-dimethylthiazol-2-y)-2, 5-diphenyltetrazolium bromide (MTT) assay system. Results: The overall survival rate was significantly higher in 25 cases of lower CYP24 expression than 17 cases of higher CYP24 expression (P <0.05); on the other hand, 23 cases of low VDR expression had a poorer prognosis than 19 cases of high VDR expression. Moreover, we disclosed that the inverse correlation between CYP24 and VDR expression is significant in esophageal cancer cases (P <0.05). Furthermore, the cell growth evaluated by MTT assay was greatly increased in CYP24-induced and VDR-diminished cells than non-responding cells by 25(OH)D3 activity (P <0.01). Conclusions: Overexpression of the candidate oncogene CYP24 is inversely correlated to vitamin D receptor expression, and may play an important role in determination of the malignant potential of esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=1342310079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342310079&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh056

DO - 10.1093/annonc/mdh056

M3 - Article

C2 - 14760115

AN - SCOPUS:1342310079

VL - 15

SP - 236

EP - 241

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -